Table 2 Current clinical trials testing TIM-3–specific antibodies in cancer patients
From: TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
Intervention (mAb) | Primary target | Study | Conditions | Clinical trial | Identifier |
|---|---|---|---|---|---|
Sym023 | TIM-3 | Advanced solid tumor malignancies or lymphomas | Metastatic cancer, solid tumor, lymphoma | Phase 1 – recruiting | NCT03489343 |
TSR-022 TSR-042 | TIM-3 PD-1 | Advanced solid tumors | Advanced or metastatic solid tumors | Phase 1 –recruiting | NCT02817633 |
TSR-022 TSR-042 | TIM-3 PD-1 | Advanced liver cancer | Liver cancer | Phase 1 – not recruiting yet | NCT03680508 |
R07121661 | TIM-3 and PD-1 (bispecific targeting) | Dose escalation study with advanced or metastatic solid tumors | Solid tumors, metastatic melanoma, NSCLC, SCLC | Phase 1 – recruiting | NCT03708328 |
MBG453 | TIM-3 | Recurring glioblastoma patients | Glioblastoma | Phase 1 – not recruiting yet | NCT03961971 |
MBG453 PDR001 | TIM-3 PD-1 | Single agent vs. combo study against advanced malignancies | Malignancies | Phase 1 – recruiting | NCT02608268 |
LY3321367 LY3300054 | TIM-3 PD-1 | Advanced relapsing/refractory solid tumors | Solid tumors | Phase 1 – recruiting | NCT03099109 |
LY3415244 | TIM-3 and PD-1 (bispecific targeting) | Advanced solid tumors | Solid tumors | Phase 1 – recruiting | NCT03752177 |
BGB-A425 Tislelozumab | TIM-3 PD-1 | Combo in advanced solid tumors | Local advanced solid tumors, metastatic solid tumors | Phase 1 –recruiting | NCT03744468 |